Dupixent® (dupilumab) – Expanded indication
October 20, 2021 - Sanofi and Regeneron announced the FDA approval of Dupixent (dupilumab), as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Top